TY - JOUR
T1 - Persuading natural killer cells to eliminate bad B cells
AU - Cooper, Laurence J.N.
PY - 2009/8/1
Y1 - 2009/8/1
N2 - Clinical trials are underway infusing T cells genetically modified to be specific for B-cell malignancies using a chimeric antigen receptor (CAR)to redirect specificity for CD19. However, issues remain about whether the CAR can provide a fully competent application signal and whether other lymphocytes with lytic capacity can target CD19+ tumors.
AB - Clinical trials are underway infusing T cells genetically modified to be specific for B-cell malignancies using a chimeric antigen receptor (CAR)to redirect specificity for CD19. However, issues remain about whether the CAR can provide a fully competent application signal and whether other lymphocytes with lytic capacity can target CD19+ tumors.
UR - http://www.scopus.com/inward/record.url?scp=68049128101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68049128101&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-0966
DO - 10.1158/1078-0432.CCR-09-0966
M3 - Comment/debate
C2 - 19638468
AN - SCOPUS:68049128101
SN - 1078-0432
VL - 15
SP - 4790
EP - 4791
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 15
ER -